145020.KQ
Hugel, Inc.
KOE · Healthcare · Biotechnology · KR
KRW 240,500.00
−2.04%Year over year
Reported trailing growth
- Revenue
- +18.9%
- EBITDA
- -13.1%
- EBIT
- +5.3%
- EPS
- +3.9%
- Free cash flow
- +10.8%
- Operating cash flow
- +13.2%
Forward estimates
Based on analyst estimates
- Revenue
- +17.7%
- EBITDA
- +19.4%
- EPS
- -11.6%
Three-year CAGR
- Revenue
- +14.7%
- EBITDA
- +24.1%
- EBIT
- +25.5%
- Net income
- +34.9%
- EPS
- +39.5%
- Free cash flow
- +56.6%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026